Drugs / Vinorelbine Bitartrate
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06107790 Background | May 2018 → Jan 2022 | HER2 positive breast carcinoma | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vinorelbine Bitartrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06107790 ↗ |
| Route | Intravenous | “Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle)” NCT06107790 ↗ |